Literature DB >> 2462252

Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.

D Teitelbaum1, R Aharoni, R Arnon, M Sela.   

Abstract

Cop 1 is a synthetic basic random copolymer of L-alanine, L-glutamic acid, L-lysine, and L-tyrosine in a residue molar ratio of 6.0:1.9:4.7:1.0 and with a molecular weight of 21,000 which proved to be effective in specific suppression of experimental allergic encephalomyelitis and has been proposed as a candidate drug against multiple sclerosis. In the present study we further investigated the mechanism of Cop 1 suppressive activity and tested whether Cop 1 could inhibit the specific T-cell response to myelin basic protein (BP). Eight BP-specific T-cell lines and clones with various H-2 restrictions and antigenic specificities were used. The responses of all these lines and clones to BP, as followed by both cell proliferation and interleukin 2 secretion assays, were affected by Cop 1. For one line, a direct cross proliferation with Cop 1 was observed, whereas in the other seven lines and clones, Cop 1 specifically inhibited the responses to BP in a competitive dose-dependent manner. The inhibition of the response to BP is specific to Cop 1, as D-Cop 1 and another random acidic polymer, poly(Tyr,Glu,Ala) (TGA), both of which were previously demonstrated to be ineffective in suppression of experimental allergic encephalomyelitis, did not inhibit the response to BP. Furthermore, Cop 1 specifically inhibited only the response of the T-cell lines and clones to BP. It did not inhibit their response to the mitogen Con A, nor did it inhibit the responses of the purified protein derivative-specific T-cell line and clone. These results suggest that Cop 1 may be effective in suppression of experimental allergic encephalomyelitis, not only because of the selective stimulation of suppressor T cells, as we have previously demonstrated, but also by specific inhibition of BP-specific effector T cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462252      PMCID: PMC282850          DOI: 10.1073/pnas.85.24.9724

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex.

Authors:  H Hirshfeld; D Teitelbaum; R Arnon; M Sela
Journal:  FEBS Lett       Date:  1970-05-01       Impact factor: 4.124

2.  Studies on the chemical basis of the antigenicity of proteins. 5. Synthesis, characterization and immunogenicity of some multichain and linear polypeptides containing tyrosine.

Authors:  M SELA; S FUCHS; R ARNON
Journal:  Biochem J       Date:  1962-10       Impact factor: 3.857

3.  In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis.

Authors:  C Webb; D Teitelbaum; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1973-05       Impact factor: 5.532

4.  Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen.

Authors:  D Teitelbaum; C Webb; A Meshorer; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1973-05       Impact factor: 5.532

5.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

6.  Induction of experimental allergic encephalomyelitis in genetically resistant strains of mice.

Authors:  Z Lando; D Teitelbaum; R Arnon
Journal:  Nature       Date:  1980-10-09       Impact factor: 49.962

7.  Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.

Authors:  D Teitelbaum; C Webb; M Bree; A Meshorer; R Arnon; M Sela
Journal:  Clin Immunol Immunopathol       Date:  1974-11

8.  Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids.

Authors:  C Webb; D Teitelbaum; A Herz; R Arnon; M Sela
Journal:  Immunochemistry       Date:  1976-04

9.  Detection of autoimmune cells proliferating to myelin basic protein and selection of T cell lines that mediate experimental autoimmune encephalomyelitis (EAE) in mice.

Authors:  A Ben-Nun; Z Lando
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

10.  T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis.

Authors:  S S Zamvil; D J Mitchell; A C Moore; K Kitamura; L Steinman; J B Rothbard
Journal:  Nature       Date:  1986 Nov 20-26       Impact factor: 49.962

View more
  25 in total

Review 1.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 2.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

3.  Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves' disease.

Authors:  Cheuk Wun Li; Roman Osman; Francesca Menconi; Erlinda Concepcion; Yaron Tomer
Journal:  J Autoimmun       Date:  2020-01-21       Impact factor: 7.094

4.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

Authors:  R Aharoni; D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

5.  Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma.

Authors:  H Schori; J Kipnis; E Yoles; E WoldeMussie; G Ruiz; L A Wheeler; M Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

Review 6.  New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  R Arnon; M Sela; D Teitelbaum
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

7.  Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.

Authors:  Y Katz-Levy; S L Kirshner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

8.  Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells.

Authors:  Zsolt Illés; Joel N H Stern; Jayagopala Reddy; Hanspeter Waldner; Marcin P Mycko; Celia F Brosnan; Stephan Ellmerich; Daniel M Altmann; Laura Santambrogio; Jack L Strominger; Vijay K Kuchroo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

9.  A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.

Authors:  P G Schlegel; R Aharoni; Y Chen; J Chen; D Teitelbaum; R Arnon; M Sela; N J Chao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

Authors:  M Fridkis-Hareli; E F Rosloniec; L Fugger; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.